Table S3.
Variable | EHa (n=979) | OH (n=979) | P-valueb |
---|---|---|---|
ICS drug prior to IPD | N/Ac | ||
Beclomethasone, n (%) | 827 (84.5%) | 827 (84.5%) | |
Fluticasone, n (%) | 22 (2.2%) | 22 (2.2%) | |
Budesonide, n (%) | 129 (13.2%) | 129 (13.2%) | |
Ciclesonide, n (%) | 1 (0.1%) | 1 (0.1%) | |
ICS drug at IPD | <0.001 | ||
Beclomethasone, n (%) | 525 (53.6%) | 827 (84.5%) | |
Fluticasone, n (%) | 0 (0.0%) | 22 (2.2%) | |
Budesonide, n (%) | 454 (46.4%) | 129 (13.2%) | |
Ciclesonide, n (%) | 0 (0.0%) | 1 (0.1%) | |
ICS dosage prior to IPD (μg)d | |||
Mean (SD) | 467.0 (238.8) | 467.0 (238.8) | N/Ac |
Median (IQR) | 400 (400, 400) | 400 (400, 400) | |
Categorized | N/Ac | ||
1–200, n (%) | 188 (19.2%) | 188 (19.2%) | |
201–400, n (%) | 561 (57.3%) | 561 (57.3%) | |
401+, n (%) | 230 (23.5%) | 230 (23.5%) | |
ICS dosage at IPD (μg)d | |||
Mean (SD) | 368.9 (162.2) | 466.2 (243.0) | <0.001 |
Median (IQR) | 400 (200, 400) | 400 (400, 400) | |
Categorized | <0.001 | ||
1–200, n (%) | 310 (31.7%) | 189 (19.3%) | |
201–400, n (%) | 592 (60.5%) | 564 (57.6%) | |
401+, n (%) | 77 (7.9%) | 226 (23.1%) | |
ICS device prior to IPD | N/Ac | ||
MDI, n (%) | 610 (62.3%) | 610 (62.3%) | |
BAI, n (%) | 182 (18.6%) | 182 (18.6%) | |
DPI, n (%) | 187 (19.1%) | 187 (19.1%) | |
ICS device at IPD | 0.984 | ||
MDI, n (%) | 0 (0.0%) | 610 (62.3%) | |
BAI, n (%) | 0 (0.0%) | 182 (18.6%) | |
DPI, n (%) | 979 (100.0%) | 187 (19.1%) |
Notes:
These patients were on OH during their baseline year but were switched to EH at IPD;
conditional logistic regression;
matching variable;
BDP-equivalents. Easyhaler® (Orion Pharma UK Ltd, Newbury, Berkshire, England). The numbers in bold are statistically significant (P<0.05).
Abbreviations: BAI, breath-actuated inhaler; BDP, beclomethasone dipropionate; DPI, dry-powder inhaler; EH, Easyhaler®; ICS, inhaled corticosteroid; IPD, index prescription date; IQR, interquartile range; MDI, metered-dose inhaler; N/A, not applicable; OH, other inhalers; SD, standard deviation.